Skip to content
Boost Up Blog – Lifestyle
Author:
Surrozen, Inc.
Surrozen Announces FDA Clearance of IND Application for SZN-8141 for the Treatment of Diabetic Macular Edema
October 2, 2026
Surrozen Submits IND for SZN-8141 to Treat Diabetic Macular Edema
September 8, 2026
Surrozen to Present at Upcoming Healthcare Investor Conferences
September 2, 2026
Surrozen Reports Second Quarter 2026 Financial Results and Provides Business Update
August 6, 2026
Surrozen to Present at Upcoming Healthcare Investor Conference
July 15, 2026
Surrozen to Present at Upcoming Healthcare Investor Conference
May 20, 2026
Surrozen Reports First Quarter 2026 Financial Results and Provides Business Update
May 6, 2026
Surrozen Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
April 28, 2026